Collagen-Electrohydrodynamic Hierarchical Lithography for Biomimetic Photonic Micro-Nanomaterials.

Biologically engineered nanomaterials give rise to unique and intriguing properties, which are not available in nature. The full-realization of such has been hindered by the lack of robust and straightforward techniques to produce the required architectures. Here a new bottomup bionano-engineering route is developed to construct nanomaterials using a guided assembly of collagen building blocks, establishing a lithographic process for three-dimensional collagen-based hierarchical micronano-architectures. By introducing optimized hybrid electro-hydrodynamic micronano-lithography exploiting collagen molecules as biological building blocks to self-assemble into a complex variety of structures, quasi-ordered mimics of metamaterials-like are constructed. The tailor-designed engineered apparatus generates the underlying substrates with vertical orientation of collagen at controlled speeds. Templating these hierarchical structures into inorganic materials allows the replication of their network into periodic metal micronano-assemblies. These generate substrates with interesting optical properties, suggesting that size-and-orientation dependent nanofilaments with varying degree of lateral order yield distinctly coloured structures with characteristic optical spectra correlated with observed colours, which varying diameters and interspacing, are attributable to coherent scattering by different periodicity of each fibrous micronano-structure. The artificial mimics display similar optical characteristics to the natural butterfly wing's structure, known to exhibit extraordinary electromagnetic properties, driving future applications in cloaking, super-lenses, photovoltaics and photodetectors.

Development and Characterization of a Probe Device toward Intracranial Spectroscopy of Traumatic Brain Injury.

Traumatic brain injury is a leading cause of mortality worldwide, often affecting individuals at their most economically active yet no primary disease-modifying interventions exist for their treatment. Real-time direct spectroscopic examination of the brain tissue within the context of traumatic brain injury has the potential to improve the understanding of injury heterogeneity and subtypes, better target management strategies and organ penetrance of pharmacological agents, identify novel targets for intervention, and allow a clearer understanding of fundamental biochemistry evolution. Here, a novel device is designed and engineered, delivering Raman spectroscopy-based measurements from the brain through clinically established cranial access techniques. Device prototyping is undertaken within the constraints imposed by the acquisition and site dimensions (standard intracranial access holes, probe's dimensions), and an artificial skull anatomical model with cortical impact is developed. The device shows a good agreement with the data acquired via a standard commercial Raman, and the spectra measured are comparable in terms of quality and detectable bands to the established traumatic brain injury model. The developed proof-of-concept device demonstrates the feasibility for real-time optical brain spectroscopic interface while removing the noise of extracranial tissue and with further optimization and in vivo validation, such technology will be directly translatable for integration into currently available standards of neurological care.

Rapid optofluidic detection of biomarkers for traumatic brain injury via surface-enhanced Raman spectroscopy.

Current technologies for the point-of-care diagnosis of traumatic brain injury (TBI) lack sensitivity, require specialist handling or involve complicated and costly procedures. Here, we report the development and testing of an optofluidic device for the rapid and label-free detection, via surface-enhanced Raman scattering (SERS), of picomolar concentrations of biomarkers for TBI in biofluids. The SERS-active substrate of the device consists of electrohydrodynamically fabricated submicrometre pillars covered with a plasmon-active nanometric gold layer, integrated in an optofluidic chip. We show that the device can detect N-acetylasparate in finger-prick blood samples from patients with TBI, and that the biomarker is released immediately from the central nervous system after TBI. The simplicity, sensitivity and robustness of SERS-integrated optofluidic technology might eventually help the triaging of TBI patients and assist clinical decision making at point-of-care settings.